SOMERVILLE, Mass., June 3, 2025 ~ Matterworks, Inc., a pioneering company in the field of predictive biology, has announced new Series A financing today. The round was led by Lewis & Clark Partners and OMX Ventures, with additional investments from Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia.

The company plans to use the funds from this round to further develop its model as a service (MaaS) business and expand its machine learning and scientific operations. This will allow Matterworks to continue its mission of unlocking unstructured molecular data for predictive biology.

Jack Geremia, CEO and Co-Founder of Matterworks, expressed his excitement about the partnership with Lewis & Clark Partners and welcomed Carolyn Fritz to the company's Board of Directors. He stated that this collaboration will accelerate their machine intelligence innovations in tackling the high cost of life science research and development.

More on Missouriar

• purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot
• purelyIV Launches Mobile Iron Infusion Therapy for Patients with Iron Deficiency Anemia
• Smile Makers Dental Care Introduces FP1: East Bay's First Robotic-Assisted Full-Arch Implant Solution for Natural, Fixed Smiles
• DCAS College opens new Representative Office in Malaysian Capital Kuala Lumpur
• Saol Therapeutics Announces Poster Presentation at the UMDF Mitochondrial Medicine 2025 Conference

Carolyn Fritz, Operating Partner at Lewis & Clark Partners, also shared her enthusiasm for the partnership. She praised Matterworks for repeatedly demonstrating how their AI platform can significantly reduce the cost and increase the efficiency of mass spectrometry quantitation. She believes that this technology has the potential to bring about a transformative shift in the field of biology.

Craig Asher, Managing Director at OMX Ventures, also expressed his support for Matterworks' innovative approach. He stated that their use of AI to unlock a new data layer for biology is as transformative as single-cell sequencing. He added that they are thrilled to be a part of this exceptional team's journey towards commercializing their groundbreaking technology.

With this new round of financing and strong partnerships in place, Matterworks is well-positioned to continue making strides in predictive biology through their cutting-edge technology.

---

Show All News | Report Violation